Holen Sie sich die Stockscreener-App
52.10
1.70%
-0.90
Vorhandelsmarkt:
51.91
-0.19
-0.36%
Schlusskurs vom Vortag:
$53.00
Offen:
$53.34
24-Stunden-Volumen:
1.68M
Relative Volume:
0.66
Marktkapitalisierung:
$13.10B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
17.27
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
-1.68%
1M Leistung:
+3.93%
6M Leistung:
+25.24%
1J Leistung:
+24.79%
1-Tages-Spanne:
$52.07
$53.35
1-Wochen-Bereich:
$52.03
$53.93
52-Wochen-Spanne:
$33.76
$53.93
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
52.10 | 13.32B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results - AD HOC NEWS
Why (EXEL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions - Yahoo Finance Singapore
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Exelixis Hits High on Growing Sales, Institutional Inflows - Yahoo Finance
Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL - MarketBeat
Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis stock hits all-time high at 52.98 USD By Investing.com - Investing.com Canada
Exelixis stock hits all-time high at 52.98 USD - Investing.com
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health - ChartMill
Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL - MarketBeat
· Analyst Forecast - MLQ.ai
Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co. - MarketBeat
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth - DirectorsTalk Interviews
Los Angeles Capital Management LLC Has $49.57 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Commonwealth Equity Services LLC Sells 259,643 Shares of Exelixis, Inc. $EXEL - MarketBeat
168,437 Shares in Exelixis, Inc. $EXEL Purchased by WINTON GROUP Ltd - MarketBeat
Norges Bank Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
EULAV Asset Management Trims Stock Position in Exelixis, Inc. $EXEL - MarketBeat
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations - Sahm
Exelixis (NASDAQ:EXEL) Reaches New 52-Week HighTime to Buy? - MarketBeat
Why Exelixis (EXEL) is a top growth stock for the long term - MSN
Exelixis, Inc. (EXEL) latest stock news and headlines - Yahoo Finance UK
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo Finance
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Marietta Investment Partners LLC Has $815,000 Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (EXEL) - Stock Traders Daily
Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Exelixis director Jack Wyszomierski sells $198,408 in shares By Investing.com - Investing.com Australia
Exelixis director Jack Wyszomierski sells $198,408 in shares - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock By Investing.com - Investing.com Australia
Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski - Stock Titan
Exelixis (EXEL) director Eckhardt sells 9,812 shares under 10b5-1 plan - Stock Titan
Exelixis Jumps 5.0% Amid Sector-Wide Rally - AlphaStreet
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis, Inc. $EXEL Shares Purchased by BNP Paribas Financial Markets - MarketBeat
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket - AOL.com
Legal & General Group Plc Sells 110,542 Shares of Exelixis, Inc. $EXEL - MarketBeat
HighTower Advisors LLC Decreases Position in Exelixis, Inc. $EXEL - MarketBeat
Geode Capital Management LLC Sells 141,796 Shares of Exelixis, Inc. $EXEL - MarketBeat
[144] EXELIXIS, INC. SEC Filing - Stock Titan
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth and Strong Analyst Support - DirectorsTalk Interviews
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Sale |
50.14 |
9,812 |
491,974 |
16,079 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):